RCS - Verici Dx PLC - ISO 27001 Information Security Certification

Verici DxAnnouncement

29/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231129:nRSc9792Ua&default-theme=true

RNS Number : 9792U  Verici Dx PLC  29 November 2023

Verici Dx plc

("Verici Dx" or the "Company")

 

ISO 27001 Information Security Certification Achieved

 

Verici Dx, a developer of advanced clinical diagnostics for organ transplant,
announces that it has attained the ISO 27001 certification for its Information
Security Management System ("ISMS").

 

ISO 27001 is an international standard specifying requirements for an ISMS,
and conformity with the standard means that Verici Dx's system meets
world-wide best practice with regards to managing risks related to the
security of data owned or handled by the Company.

 

This certification underlines Verici Dx's commitment to implementing
comprehensive security measures, ensuring the protection of sensitive data and
information, and reinforces the Company's position as a trusted partner in
industry and within patient care. With this certification, Verici Dx is
well-equipped to continue delivering innovative diagnostic solutions while
ensuring the highest level of protection for all sensitive information.

 

Dave Schultenover, VP Quality and Regulatory Affairs at Verici Dx, said: "We
are pleased to have achieved the ISO 27001 certification, which underscores
our unwavering commitment to maintaining the utmost security and
confidentiality of data within our operations."

 

Patti Connolly, Chief Operating Officer at Verici Dx, added: "Achieving this
international standard is testament to the quality of the Verici Dx team, and
the robustness of our systems and processes that maintain the highest level of
data protection for patients, clients, partners, and stakeholders."

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Sam Butcher / Jalini Kalaravy

 Walbrook PR Limited                                      Tel: 020 7933 8780 or vericidx@walbrookpr.com
                                                          (mailto:renalytix@walbrookpr.com)
 Paul McManus / Stephanie Cuthbert / Sam Allen            Mob: 07980 541 893 / 07502 558 258

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes.  The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage.  The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAMZMZMZRNGFZZ